Zurich has partnered with Reframe to offer new cancer support services to its group critical illness customers.
The partnership provides Reframe’s Cancer Support Service and Information Hub to employees covered under Zurich’s policy.
The Cancer Support Service is designed to assist those with a new cancer diagnosis, offering 28 hours of support over two years from a team that includes a cancer nurse specialist and a cancer support manager.
The service involves creating a personalised support plan to help individuals navigate NHS processes and address a range of concerns.
Customers can also access information through an online portal and receive guidance within 24 hours of registering.
Additionally, the Reframe Information Hub is available to all insured members, promoting healthy lifestyle choices and awareness of cancer symptoms to encourage early detection.
Nick Homer, head of market management, said: “We are delighted to introduce our new Cancer Support Service, provided by Reframe, for our Group Critical Illness customers.
“Reframe is a leader in cancer support and we believe customers will value the support they provide.”
Homer added: “Access to the cancer support service is available upon diagnosis – there is no requirement to meet the definition for a claim – so those that need the support can access it immediately.
“Wellbeing and prevention are also important to staying in good health which is why we’re pleased to provide insured members with access to the Reframe Information Hub as well.”
Mark Stephenson, CEO of Reframe Cancer, said: “We are proud to partner with Zurich to provide comprehensive cancer navigation and support services to their Group Critical Illness policy.
“This collaboration is a testament to our shared dedication to enhancing the well-being of individuals facing cancer.
“By integrating our CQC regulated services, we will provide insured members with the crucial clinical guidance and support they need during their cancer journey to support optimal patient outcomes, enhancing Private Medical Insurance or for the majority, NHS treatment.”
